Patients with metastatic hormonal receptor positive breast cancer
Plan to receive endocrine therapy and a CDK4/6 inhibitor (either Ribociclib or Palbociclib) in the first-line metastatic setting
Age ≥18 years
Able to provide oral consent
Willing and able to complete questionnaires as per study protocol
Patients with metastatic castrate sensitive prostate cancer
Plan to receive androgen receptor pathway inhibitor (either enzalutamide, apalutamide or abiraterone acetate) in combination with androgen deprivation therapy
Age ≥18 years
Able to provide oral consent
Willing and able to complete questionnaires as per study protocol
You may not be if
Any contraindication in taking endocrine therapy and CDK4/6 inhibitor in the morning or evening
Plan to receive abemaciclib (as this requires twice a day dosing)
Any contraindication in taking androgen receptor pathway inhibitor in the morning or evening
Plan to receive darolutamide (as this requires twice a day dosing)
Plan to receive docetaxel in combination with androgen receptor pathway inhibitor
Clareo Health | Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers
